PEGOZAFERMIN REDUCED PROGRESSION TO CIRRHOSIS: A POST-HOC ANALYSIS FROM THE PHASE 2B ENLIVEN STUDY

被引：0

作者：

Hartsfield, Cynthia ^{[1
]}

Schattenberg, Jorn ^{[2
]}

Sanyal, Arun ^{[3
]}

Abdelmalek, Manal ^{[4
]}

Margalit, Maya ^{[1
]}

Gottwald, Mildred ^{[1
]}

Feng, Shibao ^{[1
]}

Agollah, Germaine ^{[1
]}

Tseng, Leo ^{[1
]}

Mansbach, Hank ^{[1
]}

Loomba, Rohit ^{[5
]}

机构：

[1] 89bio, San Francisco, CA USA

[2] UKS, Oswego, NY USA

[3] Virginia Commonwealth Univ, Richmond, VA USA

[4] Mayo Clin Rochester, Rochester, MN USA

[5] Univ Calif San Diego, San Diego, CA USA

来源：

HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

622

引用

页码：S456 / S457

页数：2

共 50 条

[21] Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Thaci, Diamant
Tziotzios, Christos
Ito, Taisuke
Ko, Justin
Karadag, Ayse Serap
Fang, Hong
Edwards, Roger A.
Bonfanti, Gianluca
Wolk, Robert
Tran, Helen
Law, Ernest
DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2621 - 2634
[22] Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Thaci, Diamant
Tziotzios, Christos
Ito, Taisuke
Ko, Justin
Karadag, Ayse Serap
Fang, Hong
Edwards, Roger A.
Bonfanti, Gianluca
Wolk, Robert
Tran, Helen
Law, Ernest
DERMATOLOGY AND THERAPY, 2023, : 2621 - 2634
[23] ANTIHISTAMINE USE AND STRUCTURAL PROGRESSION OF KNEE OA: A POST-HOC ANALYSIS OF TWO PHASE III CLINICAL TRIALS
Bihlet, A. R.
Miller, C. P.
Byrjalsen, I.
Andersen, J. R.
Karsdal, M.
Baker, M. C.
Rao, T.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 152 - 152
[24] Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials
Bihlet, Asger
Miller, Claire
Byrjalsen, Inger
Karsdal, Morten
Andersen, Jeppe
Rao, Tharaknath
Baker, Matthew
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3742 - 3743
[25] Effect of dronedarone versus placebo on atrial fibrillation progression: a post-hoc analysis from ATHENA trail
Blomstrom-Lundqvist, C.
Naccarelli, G. V.
McKindley, D. S.
Bigot, G.
Wieloch, M.
Hohnloser, S. H.
EUROPEAN HEART JOURNAL, 2022, 43 : 573 - 573
[26] Evaluation of disease progression in patients with ATTR amyloidosis with cardiomyopathy following treatment with patisiran: post-hoc analysis of the APOLLO-B study
Damy, T.
Shah, Z.
Drachman, B.
Schwartzmann, P.
Tinoco Mesquita, C.
Polydefkis, M.
Obici, L.
Jay, P.
Bender, S.
Capocelli, K.
Hanna, M.
EUROPEAN HEART JOURNAL, 2023, 44
[27] C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Fleischmann, Roy
Connell, Carol A.
Fan, Haiyun
Strengholt, Sander
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[28] Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Hibi, Toshifumi
Motoya, Satoshi
Hisamatsu, Tadakazu
Hirai, Fumihito
Watanabe, Kenji
Matsuoka, Katsuyoshi
Saruta, Masayuki
Kobayashi, Taku
Feagan, Brian G.
Tasset, Chantal
Besuyen, Robin
Yun, Chohee
Crans, Gerald
Zhang, Jie
Kondo, Akira
Watanabe, Mamoru
INTESTINAL RESEARCH, 2022, : 110 - 125
[29] Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data
Askanase, Anca
Stach, Christian
Brittain, Claire
Stojan, George
Furie, Richard
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4622 - 4624
[30] EFFICACY OF ADALIMUMAB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: POST-HOC ANALYSES FROM A PHASE 3 STUDY
van Vollenhoven, R.
Cohen, S.
Mendelsohn, A.
Bananis, E.
Fan, H.
Takiya, L.
Fleischmann, R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1042 - 1042

← 1 2 3 4 5 →